STOCKWATCH
·
Pharmaceuticals
Quarterly Result30 Apr 2026, 03:30 pm

Laurus Labs Reports Strong FY26 Results: Revenue Up 23%, Net Profit Up 148%

AI Summary

Laurus Labs announced its Q4 and Full Year FY26 financial results. For FY26, revenues grew 23% to ₹6,813 Cr, and Net Profit surged 148% to ₹889 Cr. EBITDA increased 64% to ₹1,826 Cr, with margins expanding by 6.7% pts to 26.8%. Gross margins improved over 5% pts to 60.4%. In Q4 FY26, revenues rose 5% to ₹1,812 Cr, and EBITDA grew 10% to ₹523 Cr, achieving 28.9% margins. Net Profit for Q4 was ₹279 Cr, up 19%. The CDMO division saw significant growth, with revenues up 36% to ₹2,080 Cr in FY26. The company also declared a second interim dividend of ₹1.2 per share.

Key Highlights

  • FY26 Revenue grew 23% to ₹6,813 Cr, Net Profit surged 148% to ₹889 Cr.
  • FY26 EBITDA increased 64% to ₹1,826 Cr, with margins expanding to 26.8%.
  • CDMO division revenues grew 36% in FY26, reaching ₹2,080 Cr.
  • Q4 FY26 revenues up 5% to ₹1,812 Cr, EBITDA up 10% to ₹523 Cr.
  • Company declared a second interim dividend of ₹1.2 per share for Q4 FY26.
LAURUSLABS
Pharmaceuticals
Laurus Labs Ltd

Price Impact